Factors Predicting Reduced Antidepressant Response: Experience with the SNRI Duloxetine in Patients with Major Depression

References

• Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum IF, Sackeim HA, Kupfer DJ, Luther J, Fava M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am J Psychiatry 2006;163:1905–1917.
   PubMed Web of Science ®Google Scholar
• Kraemer HC, Wilson GT, Fairburn CG, Agras WS. Mediators and moderators of treatment effects in randomized clinical trials. Arch Gen Psychiatry 2002;59:877–883.
   PubMed Web of Science ®Google Scholar
• Nierenberg AA. Predictors of response to antidepressants: General principles and clinical implications. Psychiatr Clin N Am 2003; 26:345–352.
   PubMed Web of Science ®Google Scholar
• Hoschl C: Prediction. Nonsense or hope? Brit J Psychiatry 1993;163(Suppl 21):46–54.
   Google Scholar
• Marie-Mitchell A, Leuchter AF, Chou CP, Gauderman WJ, Azen SP. Predictors of improved mood over time in clinical trials for major depression. Psychiatry Res 2004;127:73–84.
   Google Scholar
• Bielski RJ, Friedel RO. Prediction of tricyclic antidepressant response: A critical review. Arch Gen Psychiatry 1976;33: 1479–1489.
   PubMed Web of Science ®Google Scholar
• Joyce PR, Paykel ES. Predictors of drug response in depression. Arch Gen Psychiatry 1989;46:89–99.
   PubMedGoogle Scholar
• Vallejo J, Gasto C, Catalan R, Bulbena A, Menchon JM. Predic-tors of antidepressant treatment outcome in melancholia: Psycho-social, clinical, and biological indicators. J Affect Disord 1991; 21:151–162.
   Google Scholar
• Hirschfeld RMA, Russell JM, Delgado PL, Fawcett J, Friedman RA, Harrison WM, Koran LM, Miller IW, Thase ME, Howland RH, Connolly MA, Miceli RJ. Predictors of response to acute treatment of chronic and double depression with sertraline or imipramine. J Clin Psychiatry 1998;59:669–675.
   PubMed Web of Science ®Google Scholar
• Joyce PR, Mulder RT, Luty SE, Sullivan PF, McKenzie JM, Abbott RM, Stevens IF. Patterns and predictors of remission, response, and recovery in major depression treated with fluoxetine or nortriptyline. Aust NZ J Psychiatry 2002;36:384–391.
   Google Scholar
• Flament MF, Lane RM, Zhu R, Ying Z. Predictors of an acute antidepressant response to fluoxetine and sertraline. Int Clin Psy-chopharmacol 1999;14:259–275.
   PubMed Web of Science ®Google Scholar
• Morishita S, Arita S. Clinical characteristics as predictors of response to fluvoxamine, paroxetine, and milnacipran in patients with depression. Curr Psychiatry Rev 2005;1:319–324.
   Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M, for the STAR-D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR-D: Impli-cations for clinical practice. Am J Psychiatry 2006;163:28–40.
   Google Scholar
• Mitchell PB, Schweitzer I, Burrows G, Johnson G, Polonowita A. Efficacy of venlafaxine and predictors of response in a prospec-tive open-label study of patients with treatment-resistant major depression. J Clin Psychopharmacol 2000;20:483–487.
   Google Scholar
• Trivedi MH, Morris DW, Pan JY, Grannemann BD, Rush AJ. What moderator characteristics are associated with better progno-sis for depression? Neuropsychiatr Dis Treat 2005;1:51–57.
   Google Scholar
• Kornstein SG, Wohlreich MM, Mallinckrodt CH, Watkin JG, Stewart DE. Duloxetine efficacy for major depressive disorder in male vs. female patients: Data from 7 randomized, double-blind, placebo-controlled trials. J Clin Psychiatry 2006;67: 761–770.
   Google Scholar
• Bagby RM, Ryder AG, Cristi C. Psychosocial and clinical predic-tors of response to pharmacotherapy for depression. J Psychiatry Neurosci 2002;27:250–257.
   Google Scholar
• Mulder RT. Personality pathology and treatment outcome in major depression: A review. Am J Psychiatry 2002;159:359–371.
   PubMed Web of Science ®Google Scholar
• Mazure CM, Bruce ML, Maciejewski PK, Jacobs SC. Adverse life events and cognitive-personality characteristics in the predic-tion of major depression and antidepressant response. Am J Psy-chiatry 2000;157:896–903.
   PubMed Web of Science ®Google Scholar
• Peselow ED, Robins CJ, Sanfilipio MP, Block P, Fieve RR. Sociotropy and autonomy: Relationship to antidepressant drug treatment response and endogenous-nonendogenous dichotomy. J Abn Psychol 1992;101:479–486.
   Google Scholar
• Fava M, Uebelacker LA, Alpert JE, Nierenberg AA, Pava JA, Rosenbaum JF. Major depressive subtypes and treatment response. Biol Psychiatry 1997;42:568–576.
   PubMed Web of Science ®Google Scholar
• Howland RH, Thase ME. Refractory and chronic depression: The role of axis II disorders in assessment and treatment. In: Rosenbluth M, Kennedy SH, Bagby RM, eds. Depression, and Personality: Conceptual and Clinical Challenges. Washington, DC: American Psychiatric Publishing, Inc.: 2005:157–185.
   Google Scholar
• Dodd S, Berk M. Predictors of antidepressant response: A selective review. Int J Psych Clin Pract 2004;8:91–100.
   PubMed Web of Science ®Google Scholar
• Esposito K, Goodnick P. Predictors of response in depression. Psychiatr Clin N Am 2003;26:353–365.
   PubMedGoogle Scholar
• Baton R. Biological predictors of antidepressant treatment out-come. Clin Neuropharmacol 1989;12:195–214.
   Google Scholar
• Yoshida K, Takahashi H, Higuchi H, Kamata M, Ito K, Sato K, Naito S, Shimizu T, Itoh K, Inoue K, Suzuki T, Nemeroff CB. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry 2004; 161:1575–1580.
   PubMed Web of Science ®Google Scholar
• Kraft JB, Peters EJ, Stager SL, Jenkins GD, Reinalda MS, McGrath PJ, Hamilton SP. Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. Biol Psychiatry 2007;61:734–742.
   Google Scholar
• Mulert C, Juckel G, Brunnmeier M, Karch S, Leicht G, Mergl R, Moller HJ, Hegerl U, Pogarell 0. Prediction of treatment response in major depression: Integration of concepts. J Affect Disord 2007;98: 215–225.
   Google Scholar
• Hunter AM, Leuchter AF, Morgan ML, Cook IA. Changes in brain function (quantitative EEG cordance) during placebo lead-in and treatment outcomes in clinical trials for major depression. Am J Psychiatry 2006;163:1426–1432.
   PubMed Web of Science ®Google Scholar
• Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw IL, Thompson L, Nelson DL, Hemrick-Luecke SK, Wong DT. Com-parative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychop-harmacology 2001;25:871–880.
   PubMed Web of Science ®Google Scholar
• Bech P. Kajdasz DK, Porsdal V. Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder. Psychopharmacology 2006;188:273–280.
   Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edition. Washington, DC: American Psychiatric Association: 1994.
   Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62.
   PubMed Web of Science ®Google Scholar
• Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50–55.
   PubMed Web of Science ®Google Scholar
• Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health: 1976.
   Google Scholar
• Kellner R. A symptom questionnaire. J Clin Psychiatry 1987;48:268–274.
   PubMed Web of Science ®Google Scholar
• Clayton AH, McGarvey EL, Clavet GJ. The Changes in Sexual Functioning Questionnaire (CSFQ). Development, reliability, and validity. Psychopharmacol Bull 1997;33:731–745.
   Google Scholar
• Cleary P, Guy W. Factor analysis of the Hamilton Depression Scale. Drugs Exp Clin Res 1977;1:115–120.
   Google Scholar
• Fava M. Diagnosis and definition of treatment-resistant depres-sion. Biol Psychiatry 2003;53:649–659.
   PubMed Web of Science ®Google Scholar
• Wohlreich MM, Martinez JM, Mallinckrodt CH, Prakash A, Watkin JG, Fava M. An open-label study of duloxetine for the treatment of major depressive disorder: Comparison of switching versus initiating treatment approaches. J Clin Psychopharmacol 2005;25:552–560.
   PubMed Web of Science ®Google Scholar
• Gilmer WS, Trivedi MH, Rush AJ, Wisniewski SR, Luther J, Howland RH, Yohanna D, Khan A, Alpert J. Factors associated with chronic depressive episodes: A preliminary report from the STAR*D project. Acta Psychiatr Scand 2005;112:425–433.
   Google Scholar
• Howland RH. Psychopharmacology of dysthymia. In: Alpert JE, Fava M, eds. Handbook of Chronic Depression. New York, NY: Marcel Dekker, Inc.: 2004: 139–158.
   Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, Ritz L, Biggs MM, Warden D, Luther JF, Shores-Wilson K, Niederehe G, Fava M, for the STAR-D Study Team. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. NEJM 2006;354:1231–1242.
   Google Scholar
• Fava M, Rush AJ, Alpert JE, Carmen CN, Balasubramani GK, Wisniewski SR, Trivedi MH, Biggs MM, Shores-Wilson K. What clinical and symptom features and comorbid disorders characterize outpatients with anxious major depressive disorder: A replication and extension. Can J Psychiatry 2006;51:823–834.
   Google Scholar
• Yates WR, Mitchell J, Rush AJ, Trivedi MH, Wisniewski SR, Warden D, Hauger RB, Fava M, Gaynes BN, Husain MM, Bryan C. Clinical features of depressed outpatients with and without vol. 20 no. 4 2008 co-occurring general medical conditions in STAR*D. Gen Hosp Psychiatry 2004;26: 421–429.
   Google Scholar
• Davis LL, Frazier E, Husain MM, Warden D, Trivedi M, Fava M, Cassano P. McGrath PJ, Balasubramani GK, Wisniewski SR, Rush AJ. Substance use disorder comorbidity in major depressive disorder: A confirmatory analysis of the STAR*D report. Am J Addict 2006;15:278–285.
   Google Scholar
• Iosifescu DV, Nierenberg AA, Alpert JE, Smith M, Bitran S, Dording C, Fava M. The impact of medical comorbidity on acute treatment in major depressive disorder. Am J Psychiatry 2003;160:2122–2127.
   Google Scholar
• Papakostas GI, Peterson T, Denninger J, Sonawalla SB, Mahal Y, Alpert JE, Nierenberg AA, Fava M. Somatic symptoms in treat-ment-resistant depression. Psychiatry Res 2003;118:39–45.
   Web of Science ®Google Scholar
• Fava M, Martinez JM, Greist J, Marangell LB, Brown E, Chen L, Wohlreich MM. The efficacy and tolerability of duloxetine in the treatment of anxious versus non-anxious depression: a post-hoc analysis of an open-label outpatient study. Ann Clin Psychiatry 2007;19:187–195.
   Google Scholar
• Novick JS, Stewart JW, Wisniewski SR, Cook IA, Manev R, Nierenberg AA, Rosenbaum IF, Shores-Wilson K, Balasubramani GK, Biggs MM, Zisook S, Rush AJ, for the STAR*D investiga-tors. Clinical and demographic features of atypical depression in outpatients with major depressive disorder: Preliminary findings from STAR*D. J Clin Psychiatry 2005;66:1002–1011.
   Google Scholar
• Roose SP, Miyazaki M, Devanand D, Seidman S, Fitzsimmons L, Turret N, Sackeim H. An open trial of venlafaxine for the treat-ment of late-life atypical depression. Int J Geriatr Psychiatry 2004;19:989–994.
   Google Scholar
• Marcus SM, Young EA, Kerber KB, Kornstein S, Farabaugh AH, Mitchell J, Wisniewski SR, Balasubramani GK, Trivedi MH, Rush AJ. Gender differences in depression: Findings from the STAR*D study. J Affect Disord 2005;87:141–150.
   PubMed Web of Science ®Google Scholar
• Husain MM, Rush AJ, Sackeim HA, Wisniewski SR, McClintock SM, Craven N, Holiner J, Mitchell JR, Balasubramani GK, Hauger R. Age-related characteristics of depression: A prelimi-nary STAR*D report. Am J Geriatr Psychiatry 2005;13:852–860.
   PubMed Web of Science ®Google Scholar
• Berlanga C, Flores-Ramos M. Different gender response to sero-tonergic and noradrenergic antidepressants: A comparative study of the efficacy of citalopram and reboxetine. J Affect Disord 2006;95:119–123.
   PubMed Web of Science ®Google Scholar
• Pinto-Meza A, Usall J, Serrano-Blanco A, Suarez D, Haro JM. Gender differences in response to antidepressant treatment pre-scribed in primary care: Does menopause make a difference? J Affect Disord 2006;93:53–60.
   Google Scholar
• Nelson JC, Wohlreich MM, Mallinckrodt CH, Detke MJ, Watkin JG, Kennedy JS. Duloxetine for the treatment of major depressive disor-der in older patients. Am J Geriatr Psychiatry 2005;13:227–235.
   PubMed Web of Science ®Google Scholar
• Burt VK, Wohlreich MM, Mallinckrodt CH, Detke MJ, Watkin JG, Stewart DE. Duloxetine for the treatment of major depressive disorder in women ages 40 to 55 years. Psychosomatics 2005; 46:345–354.
   PubMed Web of Science ®Google Scholar
• Thase ME, Entsuah R, Cantillon M, Komstein SG. Relative antidepressant efficacy of venlafaxine and SSRls: Sex-age inter-actions. J Women's Health 2005;14:609–616.
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, Ritz L, Nierenberg AA, Lebowitz BD, Biggs MM, Luther IF, Shores-Wilson K, Rush AJ, for the STAR-D Study Team. Medication augmentation after the failure of SSRIs for depression. NEJM 2006;354:1243–1252.
   Google Scholar
• Leuchter AF, Morgan M, Cook IA, Dunkin J, Abrams M, Witte E. Pretreatment neurophysiological and clinical characteristics of placebo responders in treatment trials for major depression. Psychopharmacology 2004;177:15–22.
   PubMed Web of Science ®Google Scholar
• Ioannidis JP. Why most published research findings are false. PLoS Med 2005;2:696–701.
   Web of Science ®Google Scholar